Literature DB >> 17182861

Evaluation of new antituberculosis drugs in mouse models.

G R Davies, A S Pym, D A Mitchison, Eric L Nuermberger, Jacques H Grosset.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17182861      PMCID： PMC1797700          DOI： 10.1128/AAC.01246-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  5 in total

1.  Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

Authors:  Eric Nuermberger; Ian Rosenthal; Sandeep Tyagi; Kathy N Williams; Deepak Almeida; Charles A Peloquin; William R Bishai; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Reactivation of latent tuberculosis: variations on the Cornell murine model.

Authors:  C A Scanga; V P Mohan; H Joseph; K Yu; J Chan; J L Flynn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils.

Authors: 
Journal:  Lancet       Date:  1978-08-12       Impact factor: 79.321

4.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

Authors:  Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Kathy Williams; Ian Rosenthal; Richard J O'Brien; Andrew A Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2004-08-11       Impact factor: 21.405

5.  Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium.

Authors:  Jasvir Dhillon; Douglas B Lowrie; Denis A Mitchison
Journal:  BMC Infect Dis       Date:  2004-11-17       Impact factor: 3.090
  5 in total
  6 in total

1.  Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.

Authors:  Emily R Driver; Gavin J Ryan; Donald R Hoff; Scott M Irwin; Randall J Basaraba; Igor Kramnik; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

2.  Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.

Authors:  Rokeya Tasneen; Sandeep Tyagi; Kathy Williams; Jacques Grosset; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

3.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12

4.  Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment.

Authors:  Donald R Hoff; Gavin J Ryan; Emily R Driver; Cornelius C Ssemakulu; Mary A De Groote; Randall J Basaraba; Anne J Lenaerts
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

5.  Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.

Authors:  Nicolas Veziris; Murad Ibrahim; Nacer Lounis; Koen Andries; Vincent Jarlier
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

Review 6.  Relevance of the Warburg Effect in Tuberculosis for Host-Directed Therapy.

Authors:  Bridgette M Cumming; Hayden T Pacl; Adrie J C Steyn
Journal:  Front Cell Infect Microbiol       Date:  2020-09-18       Impact factor: 5.293
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.